Shubham Pant, Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at MD Anderson Cancer Center, shared a post on LinkedIn:
“A couple of years ago, I had the privilege of editing a book on pancreatic cancer. At the time, it felt comprehensive. However, this week after attending American Society of Clinical Oncology (ASCO) GI26 , I walked away with a different feeling: the book already needs a major update!
The pace of progress in pancreatic cancer is genuinely remarkable. For a disease that has long been defined by limited therapeutic options, we are now seeing a rich pipeline with agents that are already in clinical trials and demonstrating benefit of PanRAS, KRAS G12D, MTAP, Immunotherapy including vaccines, Claudin 18.2, ADC’s, anti-cachexia and others!!
Looking forward to more treatment options for our patients in the near future and making long awaited progress in this devastating disease!”
More posts from ASCO GI26 on OncoDaily.